Home › Compare › ATLDF vs MRK

ATLDF vs MRK: Dividend Comparison 2026

ATLDF yields 20000000.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATLDF wins by $4.875981653489057e+49M in total portfolio value
10 years
ATLDF
ATLDF
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full ATLDF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — ATLDF vs MRK

📍 ATLDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATLDFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATLDF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ATLDF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATLDF
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, ATLDF beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATLDF + MRK for your $10,000?

ATLDF: 50%MRK: 50%
100% MRK50/50100% ATLDF
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ATLDF
No analyst data
Altman Z
-2.2
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATLDF buys
0
MRK buys
0
No recent congressional trades found for ATLDF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATLDFMRK
Forward yield20000000.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$4.875981653489057e+49M$30.7K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$4.875978515990276e+49M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ATLDF vs MRK ($10,000, DRIP)

YearATLDF PortfolioATLDF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$11,192$351.54+$2000.00M → ATLDF
2$373,835,915,712,384$373,833,775,700,934.50$12,524$392.70+$373835915.70M → ATLDF
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$14,015$438.65+$65304953364964.95M → ATLDF
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$15,682$489.96+$10661728832755499008.00M → ATLDF
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$17,547$547.23+$1.626767783781495e+24M → ATLDF
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$19,632$611.16+$2.319743300546251e+29M → ATLDF
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$21,963$682.53+$3.0915106403922057e+34M → ATLDF
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$24,571$762.18+$3.8505079858392777e+39M → ATLDF
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$27,486$851.08+$4.4821026103531426e+44M → ATLDF
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$30,745$950.29+$4.875981653489057e+49M → ATLDF

ATLDF vs MRK: Complete Analysis 2026

ATLDF — Stock

Atlanta Gold Inc. operates as a junior gold exploration and development company in the United States. Its principal property is the Atlanta gold property that covers an area of 2,159 acres located in Idaho. The company was formerly known as Twin Mining Corporation and changed its name to Atlanta Gold Inc. in March 2007. Atlanta Gold Inc. was founded in 1985 and is headquartered in Toronto, Canada.

Full ATLDF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this ATLDF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATLDF vs SCHDATLDF vs JEPIATLDF vs OATLDF vs KOATLDF vs MAINATLDF vs JNJATLDF vs ABBVATLDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.